Table 1.
Patient and disease characteristics
| PTCy alone (n = 78) | 1 associated drug (n = 204) | 2 associated drugs (n = 141) | p value | |
|---|---|---|---|---|
| Median FU (median) | 13.02 (10.13–15.9) | 23.4 (20.15–26.7) | 21.8 (15.42–28.12) | < 0.001 |
| AGE at Tx, median (range) (IQR) | 37.1 (18.1–73.7)(27.5–49.8) | 51.3 (18.7–72.9)(37.9–60.2) | 43.9 (18.1–76)(31.5–54.1) | < 0.001 |
| Time diagnosis to Tx (months) | 7.1 (2.1–81.8)(4.3–11.8) | 5.3 (1.8–225.4)(3.7–10.8) | 5.6 (0.4–186.9)(3.8–11.1) | 0.137 |
| Year of Tx, median (range) | 2014 (2009–2015) | 2013 (2008–2015) | 2013 (2009–2015) | < 0.001 |
| AML | 56 (72%) | 172 (84%) | 103 (73%) | 0.014 |
| ALL | 22 (28%) | 32 (16%) | 38 (27%) | |
| CR1 | 47 (60%) | 135 (66%) | 86 (61%) | 0.366 |
| CR2/3 | 8 (10%) | 27 (13%) | 24 (17%) | |
| Active disease | 23 (30%) | 42 (21%) | 31 (22%) | |
| MSD | 63 (81%) | 114 (56%) | 64 (45%) | < 0.001 |
| UD | 15 (19%) | 90 (44%) | 77 (54%) | |
| No F to M | 61 (78%) | 163 (82%) | 106 (76%) | 0.429 |
| F to M | 17 (22%) | 37 (18%) | 34 (24%) | |
| Missing | 0 | 4 | 1 | |
| KPS < 80 | 8 (11%) | 13 (7%) | 6 (4%) | 0.189 |
| KPS ≥ 80 | 64 (89%) | 175 (93%) | 130 (96%) | |
| Missing | 6 | 16 | 5 | |
| Pat. CMV negative | 17 (23%) | 68 (34%) | 44 (32%) | 0.218 |
| Pat. CMV positive | 57 (77%) | 133 (66%) | 92 (68%) | |
| Missing | 4 | 3 | 5 | |
| Donor CMV negative | 19 (27%) | 96 (48%) | 55 (41%) | 0.008 |
| Donor CMV positive | 51 (73%) | 103 (52%) | 80 (59%) | |
| Missing | 8 | 5 | 6 | |
| MAC | 32 (44%) | 96 (49%) | 102 (74%) | < 0.001 |
| RIC | 41 (56%) | 102 (51%) | 36 (26%) | |
| Missing | 5 | 6 | 3 | |
| BM | 58 (74%) | 25 (12%) | 25 (18%) | < 0.001 |
| PB | 20 (26%) | 179 (88%) | 116 (82%) | |
| No in vivo TCD | 78 (100%) | 130 (64%) | 72 (51%) | < 0.001 |
| In vivo TCD | 0 (0%) | 74 (36%) | 69 (49%) |
FU follow-up, CI confidence interval, IQR interquartile range, MAC myeloablative, RIC reduced intensity conditioning regimen, PTCy post-transplant cyclophosphamide, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, Tx transplant, UD unrelated donor, MSD matched sibling donor, CR complete remission, PB peripheral blood, BM bone marrow, TCD T cell depletion, CMV cytomegalovirus, KPS Karnofsky performance status